Answers are grounded in this paper and cite their sources.
Case report reveals CNS myeloma mimicking neurotoxicity in a patient receiving teclistamab therapy, indicating diagnostic challenges.
A patient with relapsing refractory multiple myeloma on teclistamab developed severe encephalopathy during dose escalation, initially concerning for ICANS but later found to have CNS myeloma.
No takes yet. Share an insight, caveat, or question.
Gummadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: